Control of beryllium powder at a DOE facility

Beryllium is contained in a number of domestic and national defense items. Although many items might contain beryllium in some manner, few people need worry about the adverse effects caused by exposure to beryllium because it is the inhalable form of beryllium that is most toxic. Chronic beryllium disease (CBD), a granulomas and fibrotic lung disease with long latency, can be developed after inhalation exposures to beryllium. It is a progressive, debilitating lung disease. Its occurrence in those exposed to beryllium has been difficult to predict because some people seem to react to low concentration exposures whereas others do not react to high concentration exposures. Onset of the disease frequently occurs between 15 to 20 years after exposure begins. Some people develop the disease after many years of low concentration exposures but others do not develop CBD even though beryllium is shown to be present in lungs and urine. Conclusions based on these experiences are that their is some immunological dependence of developing CBD in about 3--4% of the exposed population, but the exact mechanism involved has not yet been identified. Acute beryllium disease can occur after a single exposure to a concentration of greater than 0.100 mg/m3 (inhalation exposure); it is characterized by the development of chemical pneumoconiosis, a respiratory disease. The acute effect of skin contact is a dermatitis characterized by itching and reddened, elevated, or fluid-accumulated lesions which appear particularly on the exposed surfaces of the body, especially the face, neck, arms, and hands. Small particles of beryllium that enter breaks in the skin can lead to the development of granulomas and/or open sores that do not heal until the beryllium has been removed. Our interest is only airborne beryllium, which is found in areas that machine or produce beryllium